ArticleExperimental and therapeutic medicine2017
Identification of the molecular mechanisms underlying dilated cardiomyopathy via bioinformatic analysis of gene expression profiles.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Unveiling CTGF and APOA1: key hub genes and therapeutic targets in dilated cardiomyopathy.Journal of cardiothoracic surgery · 2026Article
- Comprehensive bioinformatic analysis identifies potential therapeutic drugs for CryAB (R120G)-related cardiomyopathy.BMC cardiovascular disorders · 2025Article
- Genome-wide association study of dilated cardiomyopathy-induced heart failure associated with renal insufficiency in a Chinese population.BMC cardiovascular disorders · 2023Article
- Integrated genomic analysis defines molecular subgroups in dilated cardiomyopathy and identifies novel biomarkers based on machine learning methods.Frontiers in genetics · 2023Article
- De novo and inherited variants in coding and regulatory regions in genetic cardiomyopathies.Human genomics · 2022Article
- FGF21 modulates mitochondrial stress response in cardiomyocytes only under mild mitochondrial dysfunction.Science advances · 2022Article
- An Robust Rank Aggregation and Least Absolute Shrinkage and Selection Operator Analysis of Novel Gene Signatures in Dilated Cardiomyopathy.Frontiers in cardiovascular medicine · 2021Article
- Integrated microarray analysis to identify potential biomarkers and therapeutic targets in dilated cardiomyopathy.Molecular medicine reports · 2020Article
- Integrated Analysis of Hub Genes and miRNAs in Dilated Cardiomyopathy.BioMed research international · 2020Article
- Bioinformatics analysis to identify the critical genes, microRNAs and long noncoding RNAs in melanoma.Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, gene expression profiles of patients with dilated cardiomyopathy (DCM) were re-analyzed with bioinformatics tools to investigate the molecular mechanisms underlying DCM. Gene expression dataset GSE3585 was downloaded from Gene Expression Omnibus, which included seven heart biopsy samples obtained from patients with DCM and five healthy controls. Differential analysis was performed using a Limma package in R to screen for differentially expressed genes (DEGs). Functional enrichment analysis was subsequently conducted for DEGs using the Database for Annotation, Visualization and Integration Discovery. A protein-protein interaction (PPI) network was constructed using information from Search Tool for the Retrieval of Interacting Genes software. A total of 89 DEGs were identified in the patients with DCM, including 67 upregulated and 22 downregulated genes. Functional enrichment analysis demonstrated that the downregulated genes predominantly encoded chromosomal proteins and transport-related proteins, which were significantly associated with the biological processes of 'nucleosome assembly', 'chromatin assembly', 'protein-DNA complex assembly', 'nucleosome organization' and 'DNA packaging' (H1 histone family member 0, histone cluster 1 H1c, histone cluster 1 H2bd and H2A histone family member Z). The upregulated genes detected in the present study encoded secreted proteins or phosphotransferase, which were associated with biological processes including 'cell adhesion' [connective tissue growth factor (CTGF)], 'skeletal system development' [CTGF and insulin-like growth factor binding protein 3 (IGFBP3)], 'muscle organ development' (SMAD7) and 'regulation of cell migration' [SMAD7, IGFBP3 and insulin receptor (INSR)]. Notably, signal transducer and activator of transcription 3, SMAD7, INSR, CTGF, exportin 1, IGFBP3 and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha were hub nodes with the higher degree in the PPI network. Therefore, the results of the present study suggested that DEGs may alter the biological processes of 'nucleosome formation', 'cell adhesion', 'skeletal system development', 'muscle organ development' and 'regulation of cell migration' in the development of DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.